Fidelity Investments’s BioTelemetry, Inc. BEAT Stock Holding History

Fidelity Investments’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-846	Closed	-$61K	–	4805
2020 Q4	$61K	Sell	846 -11	-1%	-$576	﹤0.01%	2972
2020 Q3	$39K	Buy	857 +52	+6%	+$2.17K	﹤0.01%	2932
2020 Q2	$36K	Sell	805 -274	-25%	-$12.3K	﹤0.01%	2866
2020 Q1	$41K	Buy	1,079 +203	+23%	+$9.35K	﹤0.01%	2811
2019 Q4	$41K	Buy	876 +154	+21%	+$6.67K	﹤0.01%	2944
2019 Q3	$30K	Buy	722 +227	+46%	+$9.8K	﹤0.01%	2981
2019 Q2	$24K	Buy	495 +104	+27%	+$5.47K	﹤0.01%	3035
2019 Q1	$24K	Sell	391 -5	-1%	-$343	﹤0.01%	2942
2018 Q4	$24K	Buy	396 +77	+24%	+$4.62K	﹤0.01%	2860
2018 Q3	$21K	Buy	+319	New	+$17.8K	﹤0.01%	2996
2015 Q4	–	Sell	-64,045	Closed	-$784K	–	2853
2015 Q3	$784K	Buy	+64,045	New	+$817K	﹤0.01%	2549

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Fidelity Investments's BEAT Position: Q1 2021 in Review

Fidelity Investments sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 846 shares — an estimated $61K sold.

Fidelity Investments first reported a position in BEAT in Q3 2015 and held it in 11 quarters. The position peaked at $784K in Q3 2015. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

Fidelity Investments reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
Fidelity Investments sold 846 BioTelemetry, Inc. shares in Q1 2021, an estimated $61K.
Fidelity Investments first reported a position in BioTelemetry, Inc. in Q3 2015 and held it in 11 quarters.
Fidelity Investments's BioTelemetry, Inc. position peaked at $784K in Q3 2015.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Fidelity Investments's 13F filing for Q1 2021, filed 14 May 2021.